Pentoxifylline, a Non-Antibiotic Drug, Promotes Adaptation of Clinical Isolates of Staphylococcus aureus via Modulating c-di-AMP Signaling
Listed in
This article is not in any list yet, why not save it to one of your lists.Abstract
This study investigated how Staphylococcus aureus adapts under pentoxifylline (PTX) therapy through analyzing three phylogenetically related isolates (L1, L2, L3) from a bacteremia patient. Whole genome sequencing revealed L1 contained a 2400-bp insertion disrupting nupC , while L3 harbored mutations in the anti-Shine-Dalgarno sequences of 16S rRNA. Each isolate evolved distinct mechanisms to reduce c-di-AMP levels, accompanied by changes in survival ability and virulence. Molecular analysis demonstrated PTX noncompetitively inhibits GdpP phosphodiesterase, directly modulating cyclic diadenosine monophosphate (c-di-AMP) signaling. Our findings provide novel insights into how non-antibiotic medications shape bacterial adaptation through second messenger modulation, highlighting the complex trade-offs between stress resistance and fitness in clinical settings.
Importance
This study reveals how pentoxifylline, a non-antibiotic drug, drives Staphylococcus aureus adaptation by modulating c-di-AMP signaling. Our findings highlight the unintended consequences of non-antibiotic medications on bacterial evolution, offering new insights for clinical treatment strategies to mitigate resistance development.
Highlights
-
PTX noncompetitively inhibits GdpP, modulating bacterial c-di-AMP signaling
-
S. aureus evolves distinct mechanisms to reduce c-di-AMP under PTX pressure
-
Non-antibiotic medications significantly shape bacterial adaptive trajectories
